Cost-Utility Analyses of Natalizumab Versus Interferon Beta-1a 44 Mcg for Rapidly Evolving Severe Relapsing-Remitting Multiple Sclerosis (RESRRMS) Patients in Brazil

✍ Scribed by Nishikawa, A.M.; Paladini, L.; Liamas, A.L.; Bueno, C.C.; Clark, O.A.C.

• Book ID: 122312352
• Publisher: John Wiley and Sons
• Year: 2013
• Tongue: English
• Weight: 60 KB
• Volume: 16
• Category: Article
• ISSN: 1098-3015
• DOI: 10.1016/j.jval.2013.08.1834